Novo Nordisk halts cell therapy work for diabetes as part of cost cuts

Published 10/10/2025, 17:12
© Reuters.

Investing.com -- Novo Nordisk A/S has discontinued its cell therapy division, which was working on finding a cure for type 1 diabetes, as part of broader cost-cutting measures.

The Danish drugmaker announced Friday it is now seeking partners to continue developing the innovations from this division. According to a report in the Borsen newspaper, almost all of the department’s 250 employees will be laid off, though Novo declined to provide specific details about the staff reductions.

This decision is part of Chief Executive Officer Mike Doustdar’s strategy to reduce Novo Nordisk’s workforce by 11% and redirect the resulting cost savings toward higher-priority research and development projects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.